Literature DB >> 11181389

New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

C Janoir1, E Varon, M D Kitzis, L Gutmann.   

Abstract

For an in vitro mutant of Streptococcus pneumoniae selected on moxifloxacin four- to eightfold-increased MICs of new fluoroquinolones, only a twofold-increased MIC of ciprofloxacin, and a twofold-decreased MIC of novobiocin were observed. This phenotype was conferred by two mutations: Ser81Phe in GyrA and a novel undescribed His103Tyr mutation in ParE, outside the quinolone resistance-determining region, in the putative ATP-binding site of topoisomerase IV.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11181389      PMCID： PMC90402          DOI： 10.1128/AAC.45.3.952-955.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands.

Authors:  D Fass; C E Bogden; J M Berger
Journal:  Nat Struct Biol       Date:  1999-04

2.  In Vivo Selection of Streptococcus pneumoniae, Resistant to Quinolones, Including Sparfloxin.

Authors:  Louis Bernard; Jean-Claude Nguyen Van; Jean-Luc Mainardi
Journal:  Clin Microbiol Infect       Date:  1995-09       Impact factor: 8.067

3.  Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.

Authors:  F L Alovero; X S Pan; J E Morris; R H Manzo; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

Authors:  V Zeller; C Janoir; M D Kitzis; L Gutmann; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Structure and mechanism of DNA topoisomerase II.

Authors:  J M Berger; S J Gamblin; S C Harrison; J C Wang
Journal:  Nature       Date:  1996-01-18       Impact factor: 49.962

6.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

7.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

9.  Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  10 in total

1.  Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.

Authors:  Emmanuelle Varon; Serge Houssaye; Sophie Grondin; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Molecular basis for different levels of tet(M) expression in Streptococcus pneumoniae clinical isolates.

Authors:  Patrick Grohs; Patrick Trieu-Cuot; Isabelle Podglajen; Sophie Grondin; Arnaud Firon; Claire Poyart; Emmanuelle Varon; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

3.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.

Authors:  Philippe Dupont; Alexandra Aubry; Emmanuelle Cambau; Laurent Gutmann
Journal:  J Bacteriol       Date:  2005-02       Impact factor: 3.490

5.  Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.

Authors:  X S Pan; G Yague; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  PCR-based ordered genomic libraries: a new approach to drug target identification for Streptococcus pneumoniae.

Authors:  Aimee E Belanger; Angel Lai; Marcia A Brackman; Donald J LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.

Authors:  Serge Houssaye; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniae.

Authors:  Farid Sifaoui; Valérie Lamour; Emmanuelle Varon; Dino Moras; Laurent Gutmann
Journal:  J Bacteriol       Date:  2003-10       Impact factor: 3.490

10.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.